Recurium IP Holdings, LLC

Merck Sharp + Dohme Corp.

Recurium IP Holding, LLC

Slap Pharmaceuticals LLC

Ahmed Abdi Samatar

Kevin Duane Bunker

Peter Qinhua Huang

Joseph Robert Pinchman

Rakesh Kumar Sit

Sunil Paliwal

Neng-Yang Shih

Alan B Cooper

Gerald Wayne Shipps, Jr

Yongqi Deng

Xiaolei Gao

Hon-Chung Tsui

Jagdish A Desai

Sobhana Babu Boga

James J-s Wang

Hugh Y Zhu

Liang Zhu

Abdul-Basit Alhassan

Yang Nan

Diane Levitan

Brian Long

Priya Dayananth

Marsha Smith

Ronald J Doll

James Han Wang

Vincent Stewart Madison

M Arshad Siddiqui

Joseph Michael Kelly

Alan W Hruza

Li Xiao

Sayee Gajanan Hegde

Robert Sun

Mehul F Patel

Tong Wang

Gerald W Shipps

Youhao Dong

Azim Alan Celebi

Fernando Donate

Yiji Wu

Lawrence Saunders Cripe

Jiali Li

Jianhui Ma

Jagdish Desai

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.

Benzamide compounds

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Multicyclic compounds

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV. 

Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER&#x3b1;).

Estrogen receptor modulators for treating mutants

The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.

IL-8 level as a determinant of responsivity of a cancer to treatment

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0. 

Compounds that are ERK inhibitors

IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Growing community of inventors

West Windsor, NJ, United States of America

Ahmed Abdi Samatar